677 related articles for article (PubMed ID: 19674994)
1. PSA doubling time as a predictive factor on repeat biopsy for detection of prostate cancer.
Shimbo M; Tomioka S; Sasaki M; Shima T; Suzuki N; Murakami S; Nakatsu H; Shimazaki J
Jpn J Clin Oncol; 2009 Nov; 39(11):727-31. PubMed ID: 19674994
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
3. Measurement of prostate specific antigen complexed to alpha1-antichymotrypsin to avoid unnecessary biopsy in patients with serum prostate specific antigen levels 4-20 ng/mL.
Nakano Y; Okamura K; Takamura S; Okamoto N; Narishima M; Yoshino Y; Hattori R; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Aug; 12(8):721-7. PubMed ID: 16174045
[TBL] [Abstract][Full Text] [Related]
4. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
[TBL] [Abstract][Full Text] [Related]
5. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
6. [Combined use of PSA density and free to total PSA ratio for cancer detection from patients with PSA elevations].
Kawai M; Okajima K; Kobayashi K; Moriyama M
Hinyokika Kiyo; 2006 Feb; 52(2):113-7. PubMed ID: 16541764
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of percent free prostate specific antigen as a predictor of prostate cancer detection on repeat biopsy.
Uemura H; Nakamura M; Hasumi H; Sugiura S; Fujinami K; Miyoshi Y; Yao M; Kubota Y
Int J Urol; 2004 Jul; 11(7):494-500. PubMed ID: 15242358
[TBL] [Abstract][Full Text] [Related]
8. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
Kamoi K; Babaian RJ
Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
[TBL] [Abstract][Full Text] [Related]
9. Free PSA/total PSA ratio increases the detection rate of prostate cancer in twelve-core biopsy.
Yokomizo Y; Miyoshi Y; Nakaigawa N; Makiyama K; Ogawa T; Yao M; Kubota Y; Uemura H
Urol Int; 2009; 82(3):280-5. PubMed ID: 19440014
[TBL] [Abstract][Full Text] [Related]
10. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
Kuruma H; Egawa S
Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
Ohigashi T; Kanao K; Kikuchi E; Nakagawa K; Nakashima J; Marumo K; Murai M
J Urol; 2005 May; 173(5):1541-5. PubMed ID: 15821482
[TBL] [Abstract][Full Text] [Related]
12. [Significance of PSA-density: analysis in PSA gray zone cases].
Ishizuka O; Iwata K; Igawa Y; Nishizawa O
Hinyokika Kiyo; 2001 Sep; 47(9):611-3. PubMed ID: 11692595
[TBL] [Abstract][Full Text] [Related]
13. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population.
Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
Jpn J Clin Oncol; 2004 Oct; 34(10):602-7. PubMed ID: 15591458
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.
Welch HG; Fisher ES; Gottlieb DJ; Barry MJ
J Natl Cancer Inst; 2007 Sep; 99(18):1395-400. PubMed ID: 17848671
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
16. Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer.
Riffenburgh RH; Amling CL
Prostate Cancer Prostatic Dis; 2003; 6(1):39-44. PubMed ID: 12664063
[TBL] [Abstract][Full Text] [Related]
17. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
[TBL] [Abstract][Full Text] [Related]
18. [Prostate cancer].
Uchida K; Akaza H
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
[TBL] [Abstract][Full Text] [Related]
19. The potential role of prebiopsy magnetic resonance imaging combined with prostate-specific antigen density in the detection of prostate cancer.
Kubota Y; Kamei S; Nakano M; Ehara H; Deguchi T; Tanaka O
Int J Urol; 2008 Apr; 15(4):322-6; discussion 327. PubMed ID: 18380820
[TBL] [Abstract][Full Text] [Related]
20. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.
Okamura K; Takaba H; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Nagasaka T
Int J Urol; 2005 Apr; 12(4):346-52. PubMed ID: 15948720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
